Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epilepsy and Neurological Disorder Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SCN8A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCN8A (Nav1.6) Fragment Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed extracellular loops. |
View SCN8A Products |
| Gene Delivery | SCN8A Promise-ORF / Lentivirus Full-length human SCN8A ORF for stable cell line generation and electrophysiology validation. |
View SCN8A Products |
| Benchmark Ab | Anti-SCN8A Recombinant Antibody Recombinant positive control for expression validation and immunofluorescence. |
View SCN8A Products |
| Validator | SCN8A siRNA Set For knockdown verification in neuronal cell models. |
View SCN8A Products |
| Related Target A | SCN1A (Nav1.1) Critical counter-screening target. SCN8A inhibitors must spare SCN1A to avoid inducing Dravet-like seizures. |
View SCN1A Products |
| Related Target B | SCN2A (Nav1.2) Highly homologous brain sodium channel. Essential for selectivity profiling of central nervous system therapeutics. |
View SCN2A Products |
| Related Target C | SCN5A (Nav1.5) Cardiac sodium channel. Mandatory counter-screening target to eliminate cardiotoxicity risks. |
View SCN5A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Multi-pass Membrane Conformation | Lentivirus-driven stable cell line development preserves native 24-transmembrane topology. |
| Subfamily Cross-Reactivity (Nav1.1/1.2/1.5) | Complete SCNx family Lentivirus and ORF panel for high-throughput counter-screening. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies and validated siRNA sets included |
| False Positives | Highly controlled host cell background controls and sequence-verified expression vectors |
Live SCN8A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SCN8A therapeutics is intensifying, with major players shifting focus from traditional non-selective anti-seizure medications to highly selective small molecule inhibitors and genetic therapies (ASOs). As first-generation therapies reach the clinic, the next wave of R&D is targeting isoform-selective modulation to maximize therapeutic index while sparing critical cardiac and central nervous system channels.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Inhibitors) | Praxis Precision Medicines, Neurocrine Biosciences / Xenon | SCN8A-Related Epilepsy (DEE13), Focal Epilepsy | Selectivity Assay (Need Lentivirus for SCN1A, SCN2A, SCN5A counter-screening) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | SCN8A Developmental & Epileptic Encephalopathy | Target Knockdown Validation (Need SCN8A siRNA and qPCR validation controls) |
| Gene Therapy / CRISPR | Encoded Therapeutics | Severe Pediatric SCN8A Encephalopathies | Expression & Functional Assay (Need SCN8A Lentivirus for stable expression profiling) |